Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation.

Federica Sora', Patrizia Chiusolo, Luca Laurenti, Gina Zini, Mario Balducci, Simona Sica, Elisabetta Metafuni, Silvia Bellesi, Sabrina Giammarco, Giuseppe Ausoni, Jolanta Alina Bajer, Giuseppe Leone

Research output: Contribution to journalArticle

Abstract

Mutations of FLT3 in AML is an entity characterized by a significant poor prognosis and are described in about 30% of AML in adults. Usually patients with this subtype of AML carrying either internal tandem duplication (ITD) or mutation at codon 835 are referred for allogeneic stem cell transplantation (ASCT) but a proportion of them would eventually relapse. The introduction of targeted therapy against FLT3 + AML is yielding conflicting results and many trials are running with new molecules. We used sorafenib, a multi-targeted tyrosine kinase inhibitor FDA approved for the treatment of advanced renal cell and hepatocellular carcinoma, on a compassionate basis in two patients with FLT3 + AML relapsing after ASCT.
Original languageEnglish
Pages (from-to)422-423
Number of pages2
JournalLeukemia Research
Volume2011
Publication statusPublished - 2010

Keywords

  • sorafenib

Fingerprint

Dive into the research topics of 'Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation.'. Together they form a unique fingerprint.

Cite this